Q-omics provides the consensus-scored SNORD93 profile across patient tissues and cancer cell-line models. SNORD93 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, SNORD93 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, SNORD93 RNA expression shows 15,904 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight COAD, HNSC, and UVM as cancer lineages where SNORD93 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORD93 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORD93 survival associations across molecular data types. SNORD93 RNA expression shows survival associations in the most cancer types (27). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORD93 RNA expression–survival associations across cancer types. High SNORD93 expression shows unfavorable associations in COAD, KIRC, KIRP, LGG and UVM, but favorable associations in UCS. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for SNORD93 RNA expression.
This table summarizes SNORD93 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SNORD93. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORD93 shows lower tumor expression in BRCA and higher tumor expression in HNSC, KIRC, KIRP, KICH and CHOL. The HNSC box plot shows higher SNORD93 RNA expression in tumor versus normal tissue (log2 FC = +0.778, t-test p < 0.001).
This table shows molecular features associated with SNORD93 in patient tissues and cancer cell lines. In patient samples, SNORD93 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
